- Home
- AUTL vs ABEO Comparison
AUTL vs ABEO Comparison
Compare AUTL & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | ABEO |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.9M | 399.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AUTL | ABEO |
|---|---|---|
| Price | $1.44 | $7.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $20.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,120,000.00 | $2,998,000.00 |
| Revenue This Year | $80.32 | $1,024.31 |
| Revenue Next Year | $53.96 | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | 258.18 |
| 52 Week Low | $1.18 | $4.00 |
| 52 Week High | $2.70 | $7.54 |
Technical Indicators
Market Signals| Indicator | AUTL | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 68.42 |
| Support Level | $1.38 | $4.97 |
| Resistance Level | $1.52 | N/A |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 11.59 | 86.99 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.